AstraZeneca Shares Fall Following News of Potential Merger

AstraZeneca, the largest drugmaker in Britain, saw its market value fall by more than £17 billion on Monday. This sharp drop in share price followed reports that the company is in discussions to buy Bristol Myers Squibb (BMS), a major US firm known for its cancer treatments. If this deal goes ahead, it would create a massive pharmaceutical group worth nearly $400 billion. According to The Guardian, this would be one of the largest deals in the history of the industry.

Before the news became public, AstraZeneca was valued at nearly £196 billion. However, after the report was first shared by the Financial Times, AstraZeneca’s shares on the London stock market fell by 8.9%. This decline caused the company to lose its position as the second-biggest listed firm in the UK, falling behind the energy company Shell. Meanwhile, shares for BMS in the United States also struggled to maintain value after the announcement.

Industry experts and analysts are currently questioning the reasons behind such a large move. A merger — the joining of two separate companies into one — is often complex. Analysts at Jefferies noted that while the deal could create a very large cancer research business, the reasons for the purchase are not yet clear. They suggested that AstraZeneca could find new products and research opportunities in other ways, such as through its existing work in China, rather than buying a large company.

Regulatory hurdles represent another major challenge for the two companies. Regulators are government agencies that ensure businesses follow the law and do not create unfair monopolies. Because both AstraZeneca and BMS have large cancer divisions, officials would likely look very closely at the deal to ensure it does not harm competition. Chris Beauchamp, a chief market analyst at IG, noted that the overlap between the companies' cancer departments is a significant problem for a successful agreement.

Shareholders, who own parts of the company, have also shown skepticism. Lucy Coutts, an investment director at JM Finn, suggested that the main benefit for AstraZeneca would be growing its presence and sales in the US. However, she noted that BMS shareholders would likely benefit more from the deal than those holding AstraZeneca stock. Another major shareholder told The Guardian that while the move is bold, there is not enough detail yet to understand if it is a good idea.

Some experts worry about the impact on the company culture. Lukas Leu, a portfolio manager at ATG Healthcare Investments, said that while a merger could help save money and expand into new areas like neuroscience, he is not a fan of such large deals. He argued that mega-mergers can sometimes stop innovation and make a company less flexible. He also questioned how the combined firm would manage to sell drugs that currently compete against each other.

Despite the negative market reaction, there is no guarantee that a deal will happen. Sources close to the situation say that while talks have taken place in recent months, nothing is certain. AstraZeneca has been working to expand its footprint in the US for some time, including a plan to invest $50 billion in research and manufacturing by 2030. The company also recently listed its shares on the New York stock exchange, which has led to some concerns that the firm might eventually move away from its UK roots.

For now, the pharmaceutical industry is watching closely. The potential merger highlights the ongoing trend of large companies trying to grow through buying others, even when investors are unsure about the risks. As the situation develops, both AstraZeneca and BMS will need to provide more clarity to their shareholders and prove that such a large investment is worth the cost. Until then, the market remains cautious about the future of these two industry giants.